Amanote Research
Register
Sign In
Discover open access scientific publications
Search, annotate, share and cite publications
Publications by Alexander Isaak
Long Term Remission and Cardiac Toxicity of a Combination of Ipilimumab and Nivolumab in a Patient With Metastatic Head and Neck Carcinoma After Progression Following Nivolumab Monotherapy
Frontiers in Oncology
Cancer Research
Oncology
Related publications
Paraneoplastic Hyperleucocytosis in a Melanoma Patient After Initiation of Ipilimumab and Nivolumab Combination Therapy
Journal for ImmunoTherapy of Cancer
Oncology
Molecular Medicine
Pharmacology
Cancer Research
Allergy
Immunology
Lung Brain Metastasis Pseudoprogression After Nivolumab and Ipilimumab Combination Treatment
Thoracic Cancer
Medicine
Pulmonary
Respiratory Medicine
Oncology
Safe Administration of Ipilimumab, Pembrolizumab, and Nivolumab in a Patient With Metastatic Melanoma, Psoriasis, and a Previous Guillain–Barré Syndrome
Case Reports in Oncological Medicine
Oncology
Nivolumab Alone and With Ipilimumab in Previously Treated Metastatic Urothelial Carcinoma: CheckMate 032 Nivolumab 1 Mg/Kg Plus Ipilimumab 3 Mg/Kg Expansion Cohort Results
Journal of Clinical Oncology
Cancer Research
Medicine
Oncology
Severe Hemophagocytic Lymphohistiocytosis in a Melanoma Patient Treated With Ipilimumab + Nivolumab
Journal for ImmunoTherapy of Cancer
Oncology
Molecular Medicine
Pharmacology
Cancer Research
Allergy
Immunology
Complete Remission of Metastatic Melanoma With Nivolumab and Complete Remission of Hepatitis C With Ledipasvir
Cancer therapy & Oncology International Journal
Nivolumab Monotherapy and Nivolumab Plus Ipilimumab in Recurrent Small Cell Lung Cancer: Results From the CheckMate 032 Randomized Cohort
Journal of Thoracic Oncology
Medicine
Oncology
Respiratory Medicine
Pulmonary
Fatal Myocarditis and Rhabdomyositis in a Patient With Stage IV Melanoma Treated With Combined Ipilimumab and Nivolumab
Current Oncology
Oncology
Vitiligo Adverse Event Observed in a Patient With Durable Complete Response After Nivolumab for Metastatic Renal Cell Carcinoma
Frontiers in Oncology
Cancer Research
Oncology
